Format

Send to

Choose Destination
Chest. 2007 Jan;131(1):180-6.

The effect of montelukast on bronchial hyperreactivity in preschool children.

Author information

1
Pediatric Pulmonology Unit, Meyer Children's Hospital, Rambam Medical Center, PO Box 9602, Haifa, 31092 Israel.

Abstract

INTRODUCTION:

The effect of montelukast therapy on bronchial hyperreactivity (BHR) as measured by the methacholine challenge test in preschool children has not yet been reported.

OBJECTIVE:

To determine the effect of montelukast (4 mg/d) on BHR as evaluated by a provocative concentration of a substance causing a 20% fall in FEV(1) (PC(20)) values in preschool asthmatic children.

PATIENTS:

A total of 26 preschool children (8 girls) aged 3.3 to 6.0 years (mean [+/- SD] age, 4.7 +/- 0.8 years) with mild asthma.

DESIGN:

Double-blind randomized, placebo controlled, crossover study. Each child received 4 weeks of treatment with 4 mg of either montelukast or placebo separated by a 2-week washout period. Primary outcomes were PC(20) values and the stage number (triple dose) at which FEV(1) values dropped by 20%(.) Post-montelukast therapy PC(20) was compared to those for the post-placebo period.

RESULTS:

Following 4 weeks of montelukast treatment, the mean PC(20) was 4.79 +/- 4.69 mg/mL, while after 4 weeks of placebo the mean PC(20) was 2.07 +/- 2.37 mg/mL (p = 0.001). The montelukast/placebo ratio for PC(20) was 2.56 with a 95% confidence interval (CI) of 1.71 to 3.99. The median difference in stage was one triple dose with a 95% CI of 0.5 to 1.5.

CONCLUSIONS:

Four weeks of treatment with montelukast resulted in a decreased BHR compared with placebo.

PMID:
17218573
DOI:
10.1378/chest.06-1402
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center